The safety of vedolizumab for ulcerative colitis and Crohn's disease

Colombel, Jean-Frédéric; E Sands, Bruce; Rutgeerts, Paul; Sandborn, William; Danese, Silvio; D'Haens, Geert; Panaccione, Remo; V Loftus, Edward; Sankoh, Serap; Fox, Irving; Parikh, Asit; Milch, Catherine; Abhyankar, Brihad; G Feagan, Brian

doi:10.1136/gutjnl-2015-311079

Public

The safety of vedolizumab for ulcerative colitis and Crohn's disease

Shared by NobleBlocks on Feb 18, 2016 • 12:00 AM UTC

Authors:

Jean-Frédéric Colombel

Bruce E Sands

Paul Rutgeerts

Abstract

Objective Vedolizumab is a gut-selective antibody to α 4 β 7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the safety of vedolizumab. Design Safety data (May 2009–June 2013) from six trials of vedolizumab were integrated. Adverse e...

Discussions